Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Rosemont Pharmaceuticals Limited
Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, Yorkshire, LS11 9XE
Telephone: +44 (0)113 244 1400
Fax: +44 (0)113 246 0738
WWW: http://www.rosemontpharma.com
Customer Care direct line: +44 (0)800 919 312
Out of Hours Telephone: +44 (0)7836 557 879
Out of Hours contact: pharmacovigilance@rosemontpharma.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 22/01/2007
SPC Arpicolin Procyclidine Hydrochloride Syrup 5mg/5ml

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/01/2007 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   10/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.4: Section included on abuse
Section 4.5: Addition of interactions with: drugs with anticholinergic properties, cholinergic properties, reduced absorption of buccal or sublingual nitrate tablets due to reduced salivation, levodopa, cisapirde, metoclopramide, domperidone, quinidine, ketoconazole, high environmental temperature, paroxetine
Section 4.8: Addition of impaired cognition and memeory, disorientation, anxiety, and agitation at high doses. Rarely psychotic-like symotioms have been reported.
Updated on 28/08/2002 and displayed until 22/01/2007
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 31/07/2002 and displayed until 28/08/2002
Reasons for adding or updating:
  • Change to section 1 - trade name
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 7 - Marketing Authorisation Holder
Updated on 14/12/2001 and displayed until 31/07/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
  procyclidine hydrochloride